Phase II trial of bi-weekly cetuximab for recurrent or metastatic colorectal cancer

Phase II trial of bi-weekly cetuximab for recurrent or metastatic colorectal cancer - B-CMAb Phase II

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006452

Enrollment

Registered

2011-11-01

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent or metastatic colorectal cancer

Interventions

bi weekly cetuximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically proven adenocarcinoma 2) KRAS wild type 3) refractory to irinotecan 4) refractory and intolerable to fluoropyrimidines 5) refractory and intolerable to oxaliplatin 6) at least one measurable lesion 7) over 20 years old 8) PS 0-2 9) without prior radiation and chemotherapy within 2 weeks 10) good organ function 11) estimated survival over 8 weeks 12) written informed consent

Exclusion criteria

Exclusion criteria: 1) without active other malignancy 2) without active infection 3) without active brain metastasis 4) without severe pulmonary diseases 5) without HBs Ag 6) without severe heart diseases 7) without pregnancy 8) without prior EGFR inhibitors 9) without other medical condition unacceptable for entry

Design outcomes

Primary

Measure	Time frame
Disease control rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026